Venture capital has been on a good run over the past few years across a range of sectors; even with recent slowdown relative to 2014-2015, venture-backed investments remain above historic averages. In fact, the first three quarters of 2016 alone are already higher than the annual rate of venture investing in all but two years since 2002.
When a scientist discovers a new drug to cure a disease, it’s cheers all around. But what happens next? How is the drug produced for commercialization so that it can actually be administered to a patient?
That’s where Michael Betenbaugh, a Whiting School of Engineering professor of chemical and biomolecular engineering, comes in. He and his laboratory team are working with researchers at MedImmune to develop a more efficient media in which to grow the microbes used to produce genetically engineered human antibodies for testing, development and commercialization.
EY has named J.W. “Bill” Marriott, Jr., Marriott (MAR) International Executive Chairman, its 2016 US EY Entrepreneur of the Year. The honor was announced at the EY Strategic Growth Forum in Palm Springs, California.
The legendary hotelier credits hard work and high expectations for his associates as two key reasons for his success. Under his more than 50 years of leadership, Marriott has grown from a family restaurant business into the world’s largest hotel chain.
GSK has recently been ranked first in the Access to Medicine Index for the fifth consecutive time, taking a leadership position in research and development, pricing, manufacturing and distribution, and product donations.
The Index, which recognises GSK for its clear access to medicines strategy and company-wide ownership, is an independent measure of the top 20 pharmaceutical companies’ efforts to improve access to healthcare in developing countries.
During the STRT1UP Roadshow, lots of companies around the state pitched on the Startup Maryland bus.
They were looking to get exposure from the video evidence it provided, but also looking to move on to the next round.
Roche said today it will launch a CHF 100 million ($100.1 million) global network of 21 academic centers focused on cancer immunotherapy R&D.
The new Centers of Research Excellence (imCORE™) Network aims to advance promising new immuno-oncology treatments by quickly carrying out preclinical and clinical research, as well as aggregating and sharing data.
AstraZeneca announced the completion of the licensing agreement between MedImmune, its global biologics research and development arm, and Allergan plc, for the global rights to MEDI2070.
MEDI2070 is an IL-23 monoclonal antibody currently in a phase IIb clinical trial for moderate-to-severe Crohn’s disease and ready for phase II for ulcerative colitis, diseases that sit outside AstraZeneca’s three main therapy areas.
A life sciences incubator formerly run by Montgomery County is now being managed by a public-private partnership that focuses on helping central Maryland scientists and bio-health startups bring their ideas to market. Rockville-based BioHealth Innovation Inc. at the start of October began managing the Germantown Innovation Center, which is part of the Pinkey Innovation Complex for Science and Technology at Montgomery
Biohealth is a hot industry in various markets across the country. Access to federal government agencies, state programs and top research institutions have led Maryland to be the No. 6 biotech market in the country, bringing in $15 billion in research dollars to the state every year. But Richard Bendis, president and CEO of Maryland
As Maryland emerges as a hotbed for research and commercial opportunities in the biohealth industry, many small businesses in this sector see the state as a good place to grow. When William Hearl started building Rockville-based Immunomic Therapeutics Inc. a decade ago, much of the initial learning curve was finding that sweet spot between creating their
